This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.
1. Three clinical questions
Does the patient have symptomatic infection? Is there an anatomic or functional reason for recurrence? Which preventive approach has a reasonable chance of helping without causing greater harm?
The 2025 AUA guidance primarily addresses otherwise healthy women with recurrent localized cystitis. The IDSA 2025 complicated-UTI guideline addresses acute treatment, not prevention of recurrent cystitis. Patients with devices, neurogenic bladder, stones, obstruction or recurrent febrile infections warrant individualized evaluation; prophylaxis trials in otherwise healthy women may not apply.
| Presentation | Clinical interpretation |
|---|---|
| New dysuria, frequency, urgency, suprapubic discomfort, sometimes visible hematuria | Compatible with acute cystitis, especially when new relative to baseline. For recurrent uncomplicated cystitis in women, AUA recommends urinalysis and urine culture with susceptibility testing for each new symptomatic episode before antibiotics. Acute symptoms, pyuria, and a uropathogen together support the diagnosis. |
| Fever, rigors, flank pain, CVA tenderness, vomiting, systemic illness | Raises concern for pyelonephritis, obstruction, bacteremia, or another source. Severity and renal function affect the need for imaging or admission. |
| Positive culture but no attributable urinary symptoms | Usually asymptomatic bacteriuria (ASB). Pyuria, odor, cloudiness, or resistance alone do not establish an antibiotic indication. Established treatment exceptions include pregnancy and endoscopic urologic procedures with anticipated mucosal trauma; some special populations remain evidence gaps. |
| Chronic urgency, nocturia, incontinence, pelvic pain without a convincing new change | Chronic baseline symptoms or pyuria alone do not establish active UTI. Noninfectious causes remain part of the differential. |
| Delirium or fall alone in an older adult with bacteriuria, no focal urinary or systemic signs | Alternative causes and the clinical course are central to assessment. Positive culture alone does not establish infection. Hemodynamic instability requires urgent sepsis assessment and treatment without assuming a urinary source. |
| Catheter or spinal cord injury | Chronic bacteriuria is expected. New fever, malaise, autonomic dysreflexia, spasticity, pelvic/flank discomfort, catheter obstruction, or other new compatible findings may prompt evaluation. Symptoms can be atypical. Stable bacteriuria alone generally does not warrant screening or treatment. |
Pyuria supports inflammation but is not proof of UTI. Absence of pyuria in a patient with typical baseline immune function should prompt reconsideration. A positive culture without a compatible syndrome may be colonization; a negative culture during symptoms warrants reassessment, particularly if collected before antibiotics.
3. When the bladder is not the source of the symptoms
| Alternative | Clues | How to evaluate |
|---|---|---|
| Genitourinary syndrome of menopause | Dryness, irritation, dyspareunia, chronic dysuria; peri/postmenopause | Focused vulvovaginal examination for atrophy and other lesions; assess vaginal symptoms and estrogen status. |
| Vaginitis, vulvitis, STI/urethritis | Discharge, pruritus, vulvar burning, new partner, urethral symptoms | Pelvic/vulvar exam, vaginal pH/wet prep or validated NAAT as appropriate; gonorrhea/chlamydia NAAT and other STI tests according to risk. |
| Overactive bladder or incontinence | Urgency/frequency without pain or inflammatory syndrome; leakage | Bladder diary, medications and fluid review, pelvic assessment; postvoid residual if retention suspected. |
| Bladder pain syndrome / interstitial cystitis | Bladder-associated pain or pressure for at least six weeks, worse with filling and relieved by voiding; repeated negative cultures | History, examination, urinalysis/culture to exclude infection; assess pelvic floor. Cystoscopy only for selected indications, not universally diagnostic. |
| Pelvic floor dysfunction | Pelvic tenderness, difficult voiding, dyspareunia, constipation | Pelvic floor examination and referral for pelvic floor physical therapy when indicated. |
| Stone, tumor, inflammatory or structural lesion | Hematuria, colicky pain, unilateral symptoms, persistent same-organism recurrence | Renal/bladder imaging; cystoscopy when indicated by hematuria risk, structural concern, or atypical course. |
| Prostatitis or urethral obstruction (men) | Perineal pain, obstructive symptoms, recurrent same organism | Focused history/exam, postvoid residual, prostate evaluation and urology referral when appropriate. Short bladder-only regimens do not provide an established course for prostatic infection. |
4. Look for a persistent reservoir when the pattern warrants it
The dates, species, susceptibilities, symptom-free intervals, and antibiotic exposure help distinguish recurrence patterns. Prompt recurrence with the same organism shortly after apparently appropriate therapy raises concern for relapse, inadequate drug exposure, retained stone, obstruction, prostatic infection, or device biofilm. Repeated different isolates separated by wellness usually represent reinfection.
| Clue | Targeted workup | Possible intervention |
|---|---|---|
| Proteus, other urease-producing organisms, recurrent same isolate, stone history, hematuria | Renal/bladder ultrasound or noncontrast CT when stone suspicion is high; assess stone burden and obstruction | Urology for infected stone or staghorn calculus management. Complete clearance of infection stones is an important source-control goal; retained infected material can sustain recurrence. |
| High residual, weak stream, prolapse, neurogenic bladder, constipation, anticholinergic use | Postvoid residual by bladder scan, medication review, pelvic/prostate examination; selective urodynamics | Correction of retention and contributory prolapse, constipation, medications, or catheterization problems may reduce recurrence. |
| Hydronephrosis, recurrent pyelonephritis, renal dysfunction, flank pain | Renal/bladder ultrasound, CT according to question and acuity; evaluate for obstruction | Urgent decompression if infected obstructed system; later definitive source control. |
| Catheter, stent, nephrostomy, foreign body | Assess indication, drainage, exchange interval and obstruction; imaging if persistent symptoms | Removal or indicated replacement addresses the device as a source. Repeated antibiotics do not reliably sterilize urine while a colonized device remains. |
| Pneumaturia/fecaluria, recurrent polymicrobial enteric flora | CT abdomen/pelvis with appropriate protocol; urology/colorectal evaluation for fistula | Source control may require correction of the fistula and associated bowel pathology. |
| Unexplained gross hematuria or persistent microscopic hematuria after infection resolves | Repeat microscopic urinalysis after presumed UTI-associated bleeding has resolved helps identify persistent hematuria. Persistent microscopic or unexplained gross hematuria warrants urologic evaluation, with risk-based cystoscopy and upper-tract imaging when indicated. | Persistent bleeding has a separate differential, including malignancy. |
5. Prevention options and what the trials actually show
| Option | Evidence / expected benefit | Tolerability, limitations and cautions |
|---|---|---|
| Vaginal estrogen, including estradiol tablets, low-dose cream, or ring | Recommended for peri/postmenopausal women with recurrent UTI when appropriate; improves local estrogen deficiency and reduces recurrence. Prevention of recurrent UTI is an off-label indication for vaginal estradiol. Systemic estrogen is not a UTI preventive substitute. | Local irritation/discharge or spotting. Unexplained bleeding and product contraindications, including estrogen-dependent cancer, thromboembolic history, and liver disease, affect suitability. Low-dose vaginal estrogen after breast cancer requires individualized discussion with oncology. Systemic absorption varies by preparation and is generally low with low-dose local therapy. |
| Increase fluids if low intake | In 140 premenopausal women drinking less than 1.5 L/day, an additional ~1.5 L water/day reduced mean cystitis episodes from 3.2 to 1.7 over 12 months. | Trial applies to low baseline intake. Fluid loading may be inappropriate with heart failure, hyponatremia, or fluid restriction and may worsen frequency/nocturia. |
| Cranberry products | Modest preventive benefit in women with recurrent UTI; the updated 2023 Cochrane review pooled eight trials with 1,555 women in this subgroup: RR 0.74 (95% CI 0.55-0.99) for symptomatic culture-verified UTI. | Juice sugar/calories, GI symptoms, inconsistent proanthocyanidin content; optimal product and dose are not established. Warfarin interaction studies conflict; changes in cranberry use can warrant closer INR monitoring. Stone history and product composition also matter; clinical stone-risk evidence is limited. |
| Methenamine hippurate | ALTAR: 1.38 versus 0.89 antibiotic-treated symptomatic episodes/person-year with methenamine versus daily antibiotic, difference 0.49 (90% CI 0.15-0.84); met prespecified noninferiority margin of 1 episode/person-year. | GI upset, dysuria, rash. Activity depends on acidic urine and can be reduced by urinary alkalinizers. The U.S. label advises against combining methenamine with sulfonamides such as TMP-SMX because insoluble precipitate can form in urine. Contraindicated with renal insufficiency, severe hepatic insufficiency, or severe dehydration by US label; no validated numerical CrCl threshold in US label. Not treatment for active UTI. Evidence is strongest in women without contributory urinary tract abnormalities. Routine vitamin C has not established an added preventive benefit. |
| Postcoital single-dose antibiotic | Effective when episodes follow intercourse; often much less antibiotic exposure than daily suppression. | Requires a clear trigger, susceptibility-informed selection; adverse effects and resistance remain possible. |
| Patient-initiated short-course treatment | Can shorten delay to treatment for patients who reliably recognize symptoms; not preventive. | A planned strategy includes urine collection before antibiotics when feasible and reassessment for nonresponse, fever, or atypical symptoms. |
| Continuous low-dose antibiotic with planned reassessment at 3-6 months | Reduces recurrences during use; most prophylaxis trials studied 6-12 months. Recurrence often returns after discontinuation. | Resistance, microbiome effects, C. difficile, drug-specific toxicity. Selection guided by cultures, allergy, renal function, tolerability, and shared decision-making. |
| D-mannose | In the 2024 placebo-controlled trial, 150/294 (51.0%) versus 161/289 (55.7%) women had a medically attended suspected UTI over six months; the difference was not statistically significant. Not recommended as a stand-alone preventive. | Cost, GI upset, and variable product quality. Preventive benefit was not established in this trial. |
| Probiotics, vitamin C, hygiene rituals | Evidence does not establish these as interchangeable preventive options. Spermicide exposure and bowel/bladder dysfunction are separate modifiable factors. | Product variability; vitamin C may raise urinary oxalate and stone risk at high doses, and does not reliably improve methenamine efficacy. |
EAU 2026 prevention guidance; ALTAR 2022; Hooton 2018; cranberry review 2023; Hayward 2024.
Antibiotic prevention is a potential option for selected nonpregnant adult women with recurrent uncomplicated cystitis. Its role differs from acute treatment and from source control for an infected device or stone. Prior cultures, renal function, contraindications, and adverse effects affect agent selection. Several uses are off-label; nitrofurantoin macrocrystal labeling includes long-term suppression. A review after three to six months can assess benefit, toxicity, and the continuing indication; indefinite treatment is not established by the prevention trials.
| Drug | Continuous prevention | Postcoital prevention | Major limitation |
|---|---|---|---|
| Nitrofurantoin macrocrystals | An established option | An established option | For bladder only. The linked US label contraindicates CrCl <60 mL/min; EAU uses eGFR <30 mL/min/1.73 m2 for cystitis treatment. These are different standards and renal estimates; short-course guidance does not establish safety of prolonged suppression in CKD. Prior nitrofurantoin-related hepatic injury is a contraindication. Pulmonary injury, hepatitis, neuropathy, and G6PD-associated hemolysis are important toxicities; symptom review and periodic renal/liver monitoring accompany prolonged exposure. Suspected toxicity warrants discontinuation and assessment. |
| Trimethoprim-sulfamethoxazole | An established option | An established option | Rash/SCAR, cytopenias, hyperkalemia, and AKI. Interactions include ACEi/ARB, spironolactone, warfarin, and methotrexate; concurrent dofetilide is contraindicated. Renal impairment changes exposure, and the US label does not recommend use below CrCl 15 mL/min. Marked hepatic damage and folate-deficiency megaloblastic anemia are contraindications. CBC, creatinine, and potassium are relevant monitoring parameters. |
| Trimethoprim alone | An established option | Continuous-prevention evidence does not establish a postcoital regimen | Hyperkalemia and marrow toxicity. Contraindicated with dofetilide or documented folate-deficiency megaloblastic anemia. The US label does not recommend use at CrCl <15 mL/min. Potassium-raising drugs and phenytoin are important interactions; creatinine, potassium, and CBC monitoring accompany prolonged use. |
| Cephalexin | An established option | An established option | GI effects, candidiasis, C. difficile and selection of resistant flora. CKD alters exposure and requires a renal dosing assessment. Cephalosporin hypersensitivity and metformin exposure are relevant; probenecid coadministration is not recommended by the US label. |
Intermittent fosfomycin is another prophylaxis option discussed in EAU guidance. This use is off-label in the United States. A prophylactic strategy does not provide treatment for pyelonephritis or prostatitis. Fluoroquinolones should generally not be used for chronic uncomplicated-cystitis suppression because of serious adverse effects and resistance selection. Nitrofurantoin and single-dose oral fosfomycin are bladder regimens, not initial treatment for upper-tract or prostatic infection. IDSA 2026 AMR guidance allows selected multidose oral fosfomycin transition for ESBL-producing E. coli cUTI after initial therapy when other oral options are unavailable. Prolonged off-label fosfomycin for chronic bacterial prostatitis is a separate specialist decision supported mainly by observational evidence.
Questions before antibiotic prevention
The indication rests on the number of symptomatic episodes, culture support, and the burden to the patient. Renal function, interactions, pregnancy status, and prior adverse effects influence suitability. A defined goal, reassessment point, and plan for breakthrough symptoms help evaluate benefit. Surveillance cultures while asymptomatic generally do not guide uncomplicated recurrent-cystitis prevention.
7. Acute treatment and follow-up
ESBL infection treatment by site · Penicillin allergy assessment
Acute treatment depends on the syndrome, prior cultures, current susceptibility, renal function, allergies, and recent antibiotic exposure. In nonpregnant adult women with uncomplicated cystitis, familiar options include five-day nitrofurantoin, three-day TMP-SMX when susceptible and appropriate, or single-dose fosfomycin for susceptible E. coli. These duration concepts come from cystitis guidance and do not extend to pregnancy, febrile UTI, or prostatic infection. In the 2018 randomized comparison, single-dose fosfomycin produced lower clinical resolution than five-day nitrofurantoin; the nitrofurantoin formulation and schedule differed from common US monohydrate/macrocrystal use. A positive culture alone does not establish a reason to escalate treatment.
Failure to begin improving within 48 hours, early recurrence, or worsening symptoms warrants reassessment. New fever, flank pain, or systemic illness requires prompt assessment for upper-tract infection or obstruction. Persistent symptoms after treatment can reflect ongoing infection or an alternative diagnosis; repeat culture helps distinguish them. Routine post-treatment cultures are generally unnecessary when symptoms resolve. An infected obstructed collecting system requires urgent drainage. NICE reassessment guidance and EAU follow-up and source-control guidance.
8. Cases for discussion
A 71-year-old with chronic frequency, no new urinary symptoms, and urine culture with ESBL E. coli. She has requested another antibiotic.
Discussion
A 39-year-old has four culture-confirmed cystitis episodes in a year, each within 48 hours after intercourse. Normal exam, no hematuria, no febrile episodes.
Discussion
A 63-year-old has recurrent Proteus bacteriuria and febrile episodes after antibiotics. She has a history of stones.
Discussion
9. Acute complicated UTI and the 2025 IDSA guideline
IV-to-oral transition · Follow-up cultures in urinary-source bacteremia
These recommendations apply to acute cUTI, including pyelonephritis, not asymptomatic bacteriuria or routine recurrent-cystitis prevention.
| Decision | Evidence and limitations |
|---|---|
| Empiric therapy | Severity, recent cultures, antibiotic exposure, adverse-effect risks, and a relevant local antibiogram inform empiric selection. Prior resistance predicts mismatch. The guideline conditionally discourages fluoroquinolones after exposure to that class in the prior 12 months. Nonseptic cUTI does not automatically require a carbapenem or a novel agent. |
| Culture results | Susceptibility results support a targeted effective regimen. Effectiveness requires adequate exposure in urine and relevant tissue, plus bloodstream exposure when bacteremia is present. |
| IV to oral | Clinical improvement, oral tolerance, and an effective oral option support transition after initial parenteral therapy. Bacteremic study participants were generally afebrile, stable, and had achieved source control. Catheterized patients, sepsis, immunocompromise, severe renal insufficiency, and structural abnormalities were commonly excluded. |
| Duration | For cUTI improving on effective therapy, the guideline conditionally supports 5-7 days of a fluoroquinolone or 7 days of a non-fluoroquinolone, counted from the first effective day. It also supports 7 rather than 14 days for improving urinary-source Gram-negative bacteremia. |
| Exceptions and uncertainty | The evidence is less applicable with inadequate source control, urinary abscess, complete obstruction, severe sepsis, devices, CKD, or substantial immunocompromise. Febrile men with suspected acute bacterial prostatitis may need 10-14 days, with limited evidence; this does not define treatment of established chronic prostatitis. Evidence for short-course oral beta-lactams is limited and depends on adequate exposure. |
Failure to improve promptly should trigger reassessment for obstruction, retained stone, abscess, inadequate drug exposure or another diagnosis rather than automatic antibiotic extension. The cUTI guideline does not provide a treatment algorithm for chronic urinary symptoms.
Advanced recurrent UTI questions
Relapse, devices and special populations
Repeated same-species growth does not prove a genetically identical strain. A short symptom-free interval after apparently adequate therapy changes the probability of a reservoir and raises questions about culture collection, adherence, drug penetration, upper tract involvement, and device/stone status. Prostatic infection in men and occult obstruction are possible explanations for febrile relapses.
Routine antibiotic prophylaxis is not supported in indwelling-catheter users or in intermittent-catheter users without recurrent symptomatic UTI. In selected adults using clean intermittent catheterization with recurrent UTI, AnTIC found fewer antibiotic-treated symptomatic episodes but increased resistance. AUA conditionally permits oral prophylaxis in neurogenic lower urinary tract dysfunction with intermittent catheterization and recurrent UTI after shared discussion of these tradeoffs. Bladder instillations in that population are an expert-opinion option with limited evidence.
Surveillance cultures in stable asymptomatic catheter users generally do not improve management. Obstruction, catheter necessity and technique, bladder pressures/emptying, and stones may explain symptomatic recurrence. Evidence from uncomplicated women is not directly applicable. In neurogenic bladder, a new change from baseline is particularly important to the diagnosis. Pregnancy has different screening, treatment and prophylaxis decisions.
Stones, urinary pH and preventive products
Struvite stones arise with urease-producing organisms; clearance of infected stone burden is part of source control. Other stones can still predispose to recurrent infection through obstruction or bacterial persistence. Stone analysis and metabolic evaluation can clarify the cause in recurrent stone formers. High-dose ascorbic acid may increase urinary oxalate. Cranberry products are not proven to prevent stones. Small metabolic studies report conflicting changes in urinary stone-risk factors, and some concentrated products increase urinary oxalate; their effect on clinical stone events remains uncertain.
Methenamine hydrolyzes to formaldehyde in acidic urine, with poor activity when urine is alkaline. Proteus may alkalinize urine, undermining efficacy. Methenamine is not a replacement for drainage of infected obstruction. US labeling contraindicates renal insufficiency without specifying a CrCl threshold and advises against combining methenamine with sulfonamides such as TMP-SMX because insoluble precipitate can form in urine. ALTAR excluded eGFR <10 mL/min/1.73 m2. That trial eligibility threshold does not override US labeling or establish safety across CKD stages.
Emerging options: separate treatment from prevention
| Approach | US status and study context | Interpretation |
|---|---|---|
| Gepotidacin (Blujepa) | FDA-approved in 2025 for susceptible uncomplicated UTI in females aged 12 years and older weighing at least 40 kg | An acute-treatment option. Label limitations include severe renal impairment (eGFR <30 mL/min), Child-Pugh C hepatic impairment, QT-prolongation risks, and major CYP3A4 interactions. The uUTI and gonorrhea indications have different interaction restrictions. Current Blujepa label. |
| Pivmecillinam (Pivya) | FDA-approved in 2024 for uncomplicated UTI in adult women due to susceptible E. coli, P. mirabilis, or S. saprophyticus | Acute treatment, not prolonged suppression. Contraindicated with serious beta-lactam hypersensitivity, inherited carnitine-deficiency disorders, or porphyria. Significant renal impairment or reduced muscle mass increases concern for carnitine depletion; valproate and other pivalate-producing drugs add risk. Current Pivya label. |
| Oral sulopenem etzadroxil/probenecid (Orlynvah) | FDA-approved in 2024 for uncomplicated UTI due to susceptible E. coli, K. pneumoniae, or P. mirabilis in adult women with limited or no alternative oral options | The U.S. label excludes complicated UTI and complicated intra-abdominal infection, including oral step-down for either. Separately, IDSA 2026 AMR guidance discusses off-label oral sulopenem as a selected alternative after initial clinical improvement in ESBL-producing Enterobacterales complicated UTI. It does not suggest oral sulopenem transition for ESBL bloodstream infection. Contraindicated with beta-lactam or probenecid hypersensitivity, known uric-acid kidney stones, or ketorolac. Not recommended with CrCl <15 mL/min or hemodialysis; probenecid contributes additional interactions. Current Orlynvah label. |
| MV140 sublingual bacterial immunotherapy | Randomized prevention data are promising; not FDA-approved for recurrent UTI prevention in the United States | Trial populations and access vary; preventive efficacy and local availability remain separate questions. |
| Intravesical hyaluronic acid, with or without chondroitin sulfate | Selected specialist prevention option; EAU recommendation is weak | The proposed role is after less invasive measures have failed. Small trials require confirmation; products and regimens vary. |
| Other bacterial vaccines, microbiome approaches, phage therapy | Investigational or variably available outside the US | Not routine substitutes for culture-based diagnosis and correction of structural problems. |
Approval for acute UTI treatment does not establish a role in prevention. Current product labeling defines the studied indication and major safety restrictions.
Evidence limits and shared decisions
ALTAR was open-label and used symptomatic episodes treated with antibiotics as its principal outcome, without requiring culture confirmation. Its noninferiority margin allowed as many as one additional episode per person-year with methenamine. The absolute event rates clarify what the noninferiority finding means to a patient. Across treatment and follow-up, four participants were hospitalized for UTI and six had a febrile UTI. All were assigned to methenamine. Event counts were small, and the study was designed around all antibiotic-treated symptomatic episodes. The trial excluded correctable urinary tract abnormalities that contributed to recurrence and neurogenic lower urinary tract dysfunction. Its protocol also excluded recurrent UTI consistently caused by Proteus, gout, severe hepatic impairment, and eGFR below 10 mL/min/1.73 m2. Long-term antibiotic prevention works during exposure but may select resistant flora.
Frequent symptom reports with repeatedly normal cultures raise a different question from culture-supported recurrence. A symptom-triggered testing plan may clarify the pattern; a positive result still requires interpretation in context. Repeated disagreement between symptoms and microbiology is a reason to reconsider the diagnosis.
Selected public sources
- AUA/CUA/SUFU recurrent uncomplicated UTI guideline, amended 2025
- EAU urological infections guideline, 2026
- IDSA asymptomatic bacteriuria guideline, 2019
- Trautner et al., IDSA complicated UTI guideline, 2025
- Harding et al., ALTAR randomized trial, BMJ 2022
- Hooton et al., water-intake randomized trial, JAMA Internal Medicine 2018
- Hayward et al., D-mannose randomized trial, 2024
- Cochrane cranberry review, updated November 2023
- Methenamine prescribing information
- Nitrofurantoin macrocrystals prescribing information
- FDA gepotidacin evidence
- MV140 placebo-controlled trial
- TMP-SMX prescribing information
- Vagifem prescribing information
- Blujepa prescribing information, revised February 2026
- IDSA AMR guidance, 2026
- Trimethoprim prescribing information
- Cephalexin prescribing information, revised October 2026
- Warfarin prescribing information, botanical interactions
- Fisher et al., AnTIC randomized trial, 2018
- AUA/SUFU neurogenic lower urinary tract dysfunction treatment guideline, 2021
- ALTAR original protocol, 2018
- AUA/SUFU microhematuria guideline, amended 2025
- EAU urolithiasis guideline, 2026, infection stones
- NICE lower UTI guideline, reassessment
- Abdul et al., cranberry-warfarin crossover study, 2008
- Ansell et al., cranberry-warfarin randomized trial, 2009
- Terris et al., cranberry concentrate and urinary oxalate, 2001
- Gettman et al., cranberry and stone-risk factors, 2005
- McHarg et al., cranberry and stone-risk factors, 2003
- Dofetilide (Tikosyn) prescribing information